The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
CAR-T Meeting 2020 | CAR T-cell therapy: a field moving fast
John Gribben, MD, DSc, FRCPath, FRCP, FMedSci, Barts Cancer Institute, London, UK, shares his highlights and discusses the importance of the 2nd European CAR T-Cell Meeting. Prof. Gribben highlights the progress observed in Europe in the last year, the use of CAR T-cells in solid tumors and gene editing. This interview took place at the 2nd European CAR T-Cell Meeting in Sitges, Spain.
